Cardiac Rehabilitation in Chronic Heart Failure: Effect of an 8-Week, High-Intensity Interval Training Versus Continuous Training

Céline Freyssin, Chantal Verkindt, PhD, Fabrice Prieur, PhD, Philippe Benaich, MD, Sébastien Maunier, Philippe Blanc, MD

ABSTRACT. Freyssin C, Verkindt C, Prieur F, Benaich P, Maunier S, Blanc P. Cardiac rehabilitation in chronic heart failure: effect of an 8-week, high-intensity interval training versus continuous training. Arch Phys Med Rehabil 2012;93: 1359-64.

Objective: To compare the effects of an 8-week, high-intensity interval training protocol versus continuous training.

Design: Randomized controlled trial.

Setting: Cardiac rehabilitation center.

Participants: Patients (N=26; mean age \pm SD, 54 \pm 12y) with chronic heart failure were enrolled in a cardiac rehabilitation program for 8 weeks.

Interventions: Patients were randomly assigned into 2 groups that performed either interval training (IT) or continuous training (CT). IT consisted of 3 sessions of 12 repetitions of 30 seconds of exercise at very high intensity, followed by 60 seconds of complete rest. The CT group performed CT exercises, which consisted of 45 minutes of aerobic exercise.

Main Outcome Measures: Parameters of gas exchanges: peak oxygen consumption (Vo_2peak), first ventilator threshold (VT1), distance at six-minute walk test (6MWT), and level of anxiety and depression were measured.

Results: The IT group increased significantly their Vo₂peak, the duration of the exercise test, the oxygen pulse, oxygen consumption at the VT1, and the distance walked during the 6MWT. The CT group only increased the time at the VT1 and the distance performed at the 6MWT. The improvement in the time at the VT1 was significantly higher for the IT group than for the CT group.

Conclusions: This study shows that IT at very high intensity for patients with heart failure appears to be more effective than CT in improving indices of submaximal exercise capacity.

Key Words: Heart failure; Rehabilitation.

© 2012 by the American Congress of Rehabilitation Medicine

PRIOR TO 1980, congestive heart failure was a contraindication to exercise. This concept has been abandoned and many randomized studies have demonstrated that an adapted

http://dx.doi.org/10.1016/j.apmr.2012.03.007

physical activity program leads to an improvement in exercise tolerance, which is an important prognosis marker for patients with heart failure.¹ Thus, exercise training in cardiac patients increases exercise duration, the first ventilatory threshold (VT1), and peak oxygen consumption (Vo2peak) by 15% to 30% without any increase in morbidity and mortality.²⁻⁴ Improvement of the VT1 is of important clinical relevance, because it leads to an improvement in the ability to tolerate submaximal exercise and in quality of life perception. Chronic exercise also improves some symptoms of chronic heart failure.¹ It was thus shown that physical exercise induced a regression of the left ventricular dysfunction markers,⁵ a decrease in vascular resistance,⁶ a reduction in the endothelial dysfunction,⁷ and an increase in the oxidative capacity of peripheral muscles.8 The management of patients with heart failure and their treatment have evolved significantly over the last decade and the benefits of cardiac rehabilitation are well-documented in the literature. Physical exercise and cardiac rehabilitation are associated with a reduction in mortality and rehospitalization.9,10 Therefore, training is now part of the recommendations in the management of heart failure.

Several types of training protocols are currently used in rehabilitation, but there is still debate regarding the intensity and type of exercise training that can provide optimal effects for chronic heart failure.¹¹ It has been demonstrated that aerobic interval training (IT) is feasible even in elderly patients with heart failure and severely impaired cardiovascular function.¹² IT can induce significant and clinically important physiologic adaptations in a population of coronary artery disease, and it was reported that improvements were to a greater extent after IT than after moderate-intensity continuous training (CT).¹³

To our knowledge, studies on the effects of IT in patients with chronic heart failure were performed using 4 repetitions of high-intensity intervals (80%–95% of Vo₂peak) of a relatively long duration (2–5min), separated by moderately intense recovery periods (50%–70% of Vo₂peak).¹³ It was suggested that the fluctuations of high oxygen requirements during IT sessions would maximize the training induced adaptations.¹⁴ Therefore,

List of Abbreviations

From the Laboratoire CURAPS – DIMPS, EA4075, Université de la Réunion, Le Tampon (Freyssin, Verkindt); Centre de rééducation Sainte Clotilde, la Réunion (Freyssin, Benaich, Maunier, Blanc); and Laboratoire CIAMS, Equipe RIME, EA 4532, Université Paris XI, Paris (Prieur), France.

No commercial party having a direct financial interest in the results of the research supporting this article has or will confer a benefit on the authors or on any organization with which the authors are associated.

Reprint requests to Céline Freyssin, Centre de rééducation Sainte Clotilde, 19 bis chemin de la clinique BP 60093, 97492 Sainte Clotilde cedex, France, e-mail: cfreyssin@gmail.com.

In-press corrected proof published online on May 8, 2012, at www.archives-pmr.org. 0003-9993/12/9308-01024\$36.00/0

IT performed with more repetitions of exercise of shorter duration and at higher intensities could be more efficient in improving exercise capacity in patients with heart failure. Moreover, the duration of the training program in previous studies was between 10¹⁵ and 40 weeks,¹⁶ which is longer than current rehabilitation programs. Consequently, it seems interesting to consider IT programs of lower duration performed at a higher intensity level with increased repetitions of shorter exercise periods, interspaced with periods of complete rest. In this context, we hypothesize that such an IT protocol could be more efficient to improve physical capacity and exercise tolerance than CT at the VT1, which is the intensity recommended by the French Cardiological Society¹⁷ and the most often used in clinical practice. Therefore, the aim of this study was to compare the benefits of an 8-week high-intensity IT with a CT in a population of patients with chronic heart failure with regard to variables commonly used in cardiac rehabilitation.

METHODS

Participants

Twenty-six patients (mean age \pm SD, 54 \pm 12y) with chronic heart failure were enrolled in an 8-week tailored multidisciplinary cardiac rehabilitation program at the Sainte Clotilde Cardiovascular Rehabilitation Center (Reunion Island, France). Criteria for inclusion were stable chronic heart failure and a left ventricular ejection fraction less than 40%. Patients have an optimized medical treatment. They received a beta-blocker, diuretic therapy. Patients were randomly assigned to 2 groups: 1 group (n=12) performed rehabilitation with interval training (IT) and 1 group (n=14) performed rehabilitation with continuous training (CT).

Study participants were matched at the beginning of the rehabilitation, according to age, sex, anthropometric criteria (weight), physical capacity (Vo₂peak, distance at the sixminute walk test [6MWT]), and smoking history (table 1). The protocol complied with the Helsinki Declaration and was approved by our local ethics committee. Informed consent was obtained from all patients.

Cardiac Rehabilitation Program

The rehabilitation program was conducted according to previously published guidelines of the French Cardiological Society.¹⁷ It was preceded by a consultation inclusion directed by a cardiologist and a clinical examination including measurement of blood pressure, echocardiography, stress testing, and blood tests. It was a multidisciplinary program of 8-weeks, and it consisted of physical activity and educational sessions. The physical activity program included 13 hours of exercise per week (2-3h/d, 5d/wk), conducted under the supervision of a physiotherapist or a sports teacher and nurse. It included 6 sessions of 71 minutes of IT or 61 minutes of CT, 4 hours of gymnastics, and 3 hours of balneotherapy (gymnastics in water). Gymnastic training consisted of a 5-minute warm-up followed by 45 minutes of strengthening exercises, stretching, and relaxation. The program also included therapeutic educational sessions on risk factors and physical practice.

After a 10-minute warm-up phase at 5W, IT consisted of 12 repetitions of 30 seconds of cycling exercise, followed by 60 seconds of complete rest. The exercise intensity was 50% and 80% of the maximal power reached during a steep ramp test during the first 4 weeks and the last 4 weeks, respectively. Each training session consisted of 3 series (12 repetitions of 30s of

Table 1: Baseline Characteristics of Patients Entering the Rehabilitation Program

$\begin{array}{c c c c c c c c c c c c c c c c c c c $	nenabilitation r logram										
Sex ratio (men/women) $7/7$ $6/6$ Body mass index (kg/m²) 24.1 ± 5.4 24.8 ± 4.0 .99Diabetics type 2 ratio $5/14$ $3/12$ Smoker $7/14$ $7/12$ Former smoker ratio $4/14$ $4/12$ Current smoker ratio $3/14$ $1/12$ Ejection fraction (%) 30.7 ± 7.8 27.8 ± 4.7 .25 \dot{V}_0_2 (mL·min·kg) 10.6 ± 4.1 10.7 ± 2.9 .90Oxygen pulse at maximal $exercise (mL/beat)$ 6.6 ± 3.3 6.2 ± 2.4 .66 $\dot{V}o_2$ at the VT1 (mL·min·kg) 7.3 ± 2.4 7.7 ± 2.3 .79Maximal workload steepramp test (W) $ 183\pm 34$ 6MWT distance (m) 423 ± 78 423 ± 98 1.00 Depression, HADS Scale 9.4 ± 4.8 8.8 ± 3.5 .74Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 .37Systolic blood pressure(mm Hg) 71 ± 14 76 ± 12 .33Cause of chronic heartfailureIschemic ratio $1/14$ $0/12$ Primary ratio $1/14$ $0/12$ Primary ratio $1/14$ $2/12$ MedicationsBetablockers ratio $14/14$ $12/12$ Antiplatelet ratio $10/14$ $7/12$ Diuretic ratio $14/14$ $12/12$ ACE ratio $12/14$ $10/12$ Antiarrhythmic ratio $8/14$ $6/12$ $6/12$	Characteristics	CT Group	IT Group	Р							
Body mass index (kg/m²) Diabetics type 2 ratio 24.1 ± 5.4 $5/14$ 24.8 ± 4.0 $3/12$.99Diabetics type 2 ratio $5/14$ $3/12$ Smoker $7/14$ $7/12$ Former smoker ratio $4/14$ $4/12$ Current smoker ratioCurrent smoker ratio $3/14$ $1/12$ Ejection fraction (%) 30.7 ± 7.8 27.8 ± 4.7 2.5 \dot{V}_{0_2} (mL·min·kg) 10.6 ± 4.1 10.7 ± 2.9 $.90$ Oxygen pulse at maximal exercise (mL/beat) 6.6 ± 3.3 6.2 ± 2.4 6.6 \dot{V}_{0_2} at the VT1 (mL·min·kg) 7.3 ± 2.4 7.3 ± 2.4 7.7 ± 2.3 $.79$ Maximal workload steep ramp test (W) $-$ 183 ± 34 1.00 Depression, HADS Scale 9.4 ± 4.8 8.8 ± 3.5 $.74$ 3.712 Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 $.37$ $.37$ Systolic blood pressure (mm Hg) 110 ± 17 114 ± 22 $.61$ Diastolic blood pressure (mm Hg) 71 ± 14 76 ± 12 $.33$ Cause of chronic heart failure $1/14$ $2/12$ $.33$ Cause of chronic heart failure $1/14$ $2/12$ $.2/14$ $10/12$ Medications $.1/14$ $2/12$ $.1/14$ $2/12$ Medications $.1/14$ $2/12$ $.1/14$ $2/12$ Acter ratio $14/14$ $12/12$ $Acter ratio14/1412/12Acter ratio14/1412/12.1/1410/12Acter ratio14/1412/12.1/1410/12Acter ratio14/1412/12.1/1410/12Acter ratio$	Age (y)	55±12	54±9	.08							
Diabetics type 2 ratio $5/14$ $3/12$ SmokerNonsmoker ratio $7/14$ $7/12$ Former smoker ratio $4/14$ $4/12$ Current smoker ratio $3/14$ $1/12$ Ejection fraction (%) 30.7 ± 7.8 27.8 ± 4.7 .25 $\dot{V}o_2$ (mL·min·kg) 10.6 ± 4.1 10.7 ± 2.9 .90Oxygen pulse at maximalexercise (mL/beat) 6.6 ± 3.3 6.2 ± 2.4 .66 $\dot{V}o_2$ at the VT1 (mL·min·kg) 7.3 ± 2.4 7.7 ± 2.3 .79Maximal workload steepramp test (W)- 183 ± 34 6MWT distance (m) 423 ± 78 423 ± 98 1.00 Depression, HADS Scale 9.4 ± 4.8 8.8 ± 3.5 .74Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 .37Systolic blood pressure(mm Hg) 110 ± 17 114 ± 22 .61Diastolic blood pressure(mm Hg) 71 ± 14 76 ± 12 .33Cause of chronic heartfailureIschemic ratio $1/14$ $0/12$ Primary ratio $1/14$ $0/12$ MedicationsImage: State Sta	Sex ratio (men/women)	7/7	6/6								
Smoker Nonsmoker ratio 7/14 7/12 Former smoker ratio 4/14 4/12 Current smoker ratio 3/14 1/12 Ejection fraction (%) 30.7 ± 7.8 27.8 ± 4.7 .25 $\dot{V}o_2$ (mL·min·kg) 10.6 ± 4.1 10.7 ± 2.9 .90 Oxygen pulse at maximal exercise (mL/beat) 6.6 ± 3.3 6.2 ± 2.4 .66 $\dot{V}o_2$ at the VT1 (mL·min·kg) 7.3 ± 2.4 7.7 ± 2.3 .79 Maximal workload steep ramp test (W) - 183 ± 34 6MWT distance (m) 423 ± 78 423 ± 98 1.00 Depression, HADS Scale 9.4 ± 4.8 8.8 ± 3.5 .74 Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 .37 Systolic blood pressure (mm Hg) 110 ± 17 114 ± 22 .61 Diastolic blood pressure (mm Hg) 71 ± 14 76 ± 12 .33 Cause of chronic heart failure .33 .34 .34 Ischemic ratio $1/14$ $0/12$.33 .34 Alcoholism ratio $1/14$	Body mass index (kg/m ²)	24.1±5.4	24.8±4.0	.99							
Nonsmoker ratio7/147/12Former smoker ratio4/144/12Current smoker ratio3/141/12Ejection fraction (%) 30.7 ± 7.8 27.8 ± 4.7 .25 $\dot{V}o_2$ (mL-min·kg) 10.6 ± 4.1 10.7 ± 2.9 .90Oxygen pulse at maximalexercise (mL/beat) 6.6 ± 3.3 6.2 ± 2.4 .66 $\dot{V}o_2$ at the VT1 (mL·min·kg) 7.3 ± 2.4 7.7 ± 2.3 .79Maximal workload steepramp test (W)- 183 ± 34 6MWT distance (m) 423 ± 78 423 ± 98 1.00 Depression, HADS Scale 9.4 ± 4.8 8.8 ± 3.5 .74Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 .37Systolic blood pressure(mm Hg) 110 ± 17 114 ± 22 .61Diastolic blood pressure(mm Hg) 71 ± 14 76 ± 12 .33Cause of chronic heartfailure.33Cause of chronic heartfailure1/140/12.4.4MedicationsBetablockers ratio1/141/12Antiplatelet ratio10/147/12Diuretic ratio14/1412/12AcE ratio12/1410/12Alcoholism ratio14/1412/12Antiplatelet ratio10/147/12Diuretic ratio14/1412/12AcE ratio12/1410/12Antiarrhythmic ratio8/146/12	Diabetics type 2 ratio	5/14	3/12								
Former smoker ratio $4/14$ $4/12$ Current smoker ratio $3/14$ $1/12$ Ejection fraction (%) 30.7 ± 7.8 27.8 ± 4.7 .25 $\dot{V}o_2$ (mL·min·kg) 10.6 ± 4.1 10.7 ± 2.9 .90Oxygen pulse at maximal exercise (mL/beat) 6.6 ± 3.3 6.2 ± 2.4 .66 $\dot{V}o_2$ at the VT1 (mL·min·kg) 7.3 ± 2.4 7.7 ± 2.3 .79Maximal workload steep ramp test (W)- 183 ± 34 6MWT distance (m) 423 ± 78 423 ± 98 1.00Depression, HADS Scale 9.4 ± 4.8 8.8 ± 3.5 .74Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 .37Systolic blood pressure (mm Hg) 110 ± 17 114 ± 22 .61Diastolic blood pressure (mm Hg) 71 ± 14 76 ± 12 .33Cause of chronic heart failure $1/14$ $0/12$.33Cause of chronic neart failure $1/14$ $0/12$ Primary ratio $1/14$ $0/12$.33Betablockers ratio $14/14$ $12/12$ Antiplatelet ratio $10/14$ $7/12$ Diuretic ratio $14/14$ $12/12$ AcE ratio $12/14$ $10/12$ Antiarrhythmic ratio $8/14$ $6/12$	Smoker										
Current smoker ratio $3/14$ $1/12$ Ejection fraction (%) 30.7 ± 7.8 27.8 ± 4.7 .25 \dot{Vo}_2 (mL·min·kg) 10.6 ± 4.1 10.7 ± 2.9 .90Oxygen pulse at maximal exercise (mL/beat) 6.6 ± 3.3 6.2 ± 2.4 .66 \dot{Vo}_2 at the VT1 (mL·min·kg) 7.3 ± 2.4 7.7 ± 2.3 .79Maximal workload steep ramp test (W)- 183 ± 34 6MWT distance (m) 423 ± 78 423 ± 98 1.00Depression, HADS Scale 9.4 ± 4.8 8.8 ± 3.5 .74Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 .37Systolic blood pressure (mm Hg) 110 ± 17 114 ± 22 .61Diastolic blood pressure (mm Hg) 71 ± 14 76 ± 12 .33Cause of chronic heart failure $1/14$ $0/12$ Primary ratio $1/14$ $0/12$ Primary ratio $1/14$ $2/12$ Medications $8etablockers ratio$ $14/14$ Diuretic ratio $10/14$ $7/12$ Diuretic ratio $14/14$ $12/12$ AcE ratio $12/14$ $10/12$ Antiarrhythmic ratio $8/14$ $6/12$	Nonsmoker ratio	7/14	7/12								
Ejection fraction (%) 30.7 ± 7.8 27.8 ± 4.7 .25 \dot{Vo}_2 (mL·min·kg) 10.6 ± 4.1 10.7 ± 2.9 .90 $Oxygen pulse at maximalexercise (mL/beat)6.6\pm3.36.2\pm2.4.66\dot{Vo}_2 at the VT1 (mL·min·kg)7.3\pm2.47.7\pm2.3.79Maximal workload steepramp test (W)-183\pm34.00Depression, HADS Scale9.4\pm4.88.8\pm3.5.74Anxiety, HADS Scale7.7\pm2.3.66\pm1.8.37Systolic blood pressure(mm Hg)110\pm17114\pm22.61Diastolic blood pressure(mm Hg)71\pm1476\pm12.33Cause of chronic heartfailure1/140/12Primary ratio1/140/12Primary ratio1/142/12Medications8etablockers ratio14/14Diuretic ratio14/1412/12AcE ratio12/1410/12Antiarrhythmic ratio8/146/12$	Former smoker ratio	4/14	4/12								
$\begin{array}{cccccc} \dot{\rm Vo}_2 \ (\rm mL\cdot min\cdot kg) & 10.6 \pm 4.1 & 10.7 \pm 2.9 & .90 \\ Oxygen pulse at maximal \\ exercise \ (\rm mL/beat) & 6.6 \pm 3.3 & 6.2 \pm 2.4 & .66 \\ \dot{\rm Vo}_2 \ at \ the \ VT1 \ (\rm mL\cdot min\cdot kg) & 7.3 \pm 2.4 & 7.7 \pm 2.3 & .79 \\ Maximal \ workload \ steep \\ ramp \ test \ (W) & - & 183 \pm 34 \\ 6MWT \ distance \ (m) & 423 \pm 78 & 423 \pm 98 & 1.00 \\ Depression, \ HADS \ Scale & 9.4 \pm 4.8 & 8.8 \pm 3.5 & .74 \\ Anxiety, \ HADS \ Scale & 7.7 \pm 2.3 & 6.6 \pm 1.8 & .37 \\ Systolic \ blood \ pressure \\ (mm \ Hg) & 110 \pm 17 & 114 \pm 22 & .61 \\ Diastolic \ blood \ pressure \\ (mm \ Hg) & 71 \pm 14 & 76 \pm 12 & .33 \\ Cause \ of \ chronic \ heart \\ failure \\ Ischemic \ ratio & 1/14 & 0/12 \\ Primary \ ratio & 1/14 & 0/12 \\ Primary \ ratio & 1/14 & 2/12 \\ Medications \\ Betablockers \ ratio & 14/14 & 12/12 \\ Antiplatelet \ ratio & 10/14 & 7/12 \\ Diuretic \ ratio & 14/14 & 12/12 \\ ACE \ ratio & 12/14 & 10/12 \\ Antiarrhythmic \ ratio & 8/14 & 6/12 \\ \end{array}$	Current smoker ratio	3/14	1/12								
Oxygen pulse at maximal 6.6±3.3 6.2 ± 2.4 .66 $\dot{V}o_2$ at the VT1 (mL·min·kg) 7.3 ± 2.4 7.7 ± 2.3 .79 Maximal workload steep ramp test (W) – 183±34 6MWT distance (m) 423±78 423±98 1.00 Depression, HADS Scale 9.4 ± 4.8 8.8 ± 3.5 .74 Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 .37 Systolic blood pressure (mm Hg) 110±17 114±22 .61 Diastolic blood pressure (mm Hg) 71 ± 14 76 ± 12 .33 Cause of chronic heart failure .33 Cause of chronic heart .34 failure 12/14 10/12 .41/4 .42/12 Medications 1/14 0/12 .33 Betablockers ratio 14/14 12/12 .41/14 Antiplatelet ratio 10/14 7/12 .41/14 Diuretic ratio 14/14 12/12 .42/12 Medications 14/14 12/12 .42/12 Antiplatelet ratio 10/14 7/12 .11/14 .42/12	Ejection fraction (%)	30.7±7.8	.25								
exercise (mL/beat) 6.6 ± 3.3 6.2 ± 2.4 .66 $\dot{V}o_2$ at the VT1 (mL·min·kg) 7.3 ± 2.4 7.7 ± 2.3 .79 Maximal workload steep ramp test (W) - 183 ± 34 6MWT distance (m) 423 ± 78 423 ± 98 1.00 Depression, HADS Scale 9.4 ± 4.8 8.8 ± 3.5 .74 Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 .37 Systolic blood pressure (mm Hg) 110 ± 17 114 ± 22 .61 Diastolic blood pressure (mm Hg) 71 ± 14 76 ± 12 .33 Cause of chronic heart failure Ischemic ratio $1/14$ $0/12$ Primary ratio $1/14$ $0/12$ Medications Betablockers ratio $14/14$ $12/12$ Antiplatelet ratio $10/14$ $7/12$ Diuretic ratio $14/14$ $12/12$ ACE ratio $12/14$ $10/12$ ACE ratio $12/14$ $10/12$	Vo₂ (mL·min·kg)	10.6±4.1	10.7±2.9	.90							
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Oxygen pulse at maximal										
Maximal workload steep ramp test (W)- 183 ± 34 6MWT distance (m) 423 ± 78 423 ± 98 1.00 Depression, HADS Scale 9.4 ± 4.8 8.8 ± 3.5 $.74$ Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 $.37$ Systolic blood pressure (mm Hg) 110 ± 17 114 ± 22 $.61$ Diastolic blood pressure (mm Hg) 71 ± 14 76 ± 12 $.33$ Cause of chronic heart failure $1/14$ $0/12$ $.33$ Primary ratio $1/14$ $0/12$ $.33$ Betablockers ratio $1/14$ $2/12$ $.4/14$ Medications $.1/14$ $.2/12$ Metications $.1/14$ $.2/12$ Antiplatelet ratio $.1/14$ $.1/12$ Diuretic ratio $.1/14$ $.1/12$ AcE ratio $.1/14$ $.1/12$ Antiarrhythmic ratio $.1/14$ $.6/12$	exercise (mL/beat)	6.6±3.3	6.2±2.4	.66							
$\begin{array}{ccccc} ramp test (W) & - & 183 \pm 34 \\ 6MWT distance (m) & 423 \pm 78 & 423 \pm 98 & 1.00 \\ Depression, HADS Scale & 9.4 \pm 4.8 & 8.8 \pm 3.5 & .74 \\ Anxiety, HADS Scale & 7.7 \pm 2.3 & 6.6 \pm 1.8 & .37 \\ Systolic blood pressure & & & & & \\ (mm Hg) & 110 \pm 17 & 114 \pm 22 & .61 \\ Diastolic blood pressure & & & & & \\ (mm Hg) & 71 \pm 14 & 76 \pm 12 & .33 \\ Cause of chronic heart & & & & & \\ failure & & & & & \\ Ischemic ratio & 12/14 & 10/12 & \\ Alcoholism ratio & 1/14 & 0/12 & \\ Primary ratio & 1/14 & 0/12 & \\ Primary ratio & 1/14 & 12/12 & \\ Medications & & & \\ Betablockers ratio & 14/14 & 12/12 & \\ Antiplatelet ratio & 10/14 & 7/12 & \\ Diuretic ratio & 14/14 & 12/12 & \\ ACE ratio & 12/14 & 10/12 & \\ Antiarrhythmic ratio & 8/14 & 6/12 & \\ \end{array}$	Vo₂ at the VT1 (mL·min·kg)	7.3±2.4	7.7±2.3	.79							
6MWT distance (m) 423 ± 78 423 ± 98 1.00 Depression, HADS Scale 9.4 ± 4.8 8.8 ± 3.5 $.74$ Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 $.37$ Systolic blood pressure $(mm Hg)$ 110 ± 17 114 ± 22 $.61$ Diastolic blood pressure $(mm Hg)$ 71 ± 14 76 ± 12 $.33$ Cause of chronic heart $failure$ $1/14$ $0/12$ Ischemic ratio $1/14$ $0/12$ $Primary ratio$ $1/14$ $2/12$ Medications 8 $14/14$ $12/12$ $Antiplatelet ratio$ $14/14$ $12/12$ Antiplatelet ratio $10/14$ $7/12$ $10/12$ $ACE ratio$ $12/14$ $10/12$	Maximal workload steep										
Depression, HADS Scale 9.4 ± 4.8 8.8 ± 3.5 .74Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 .37Systolic blood pressure 110 ± 17 114 ± 22 .61Diastolic blood pressure 110 ± 17 114 ± 22 .61Diastolic blood pressure 71 ± 14 76 ± 12 .33Cause of chronic heart $12/14$ $10/12$ failure $1/14$ $0/12$ Primary ratio $1/14$ $0/12$ Primary ratio $1/14$ $2/12$ Medications $8etablockers ratio$ $14/14$ Diuretic ratio $10/14$ $7/12$ Diuretic ratio $14/14$ $12/12$ ACE ratio $12/14$ $10/12$ Antiarrhythmic ratio $8/14$ $6/12$	ramp test (W)	-	183±34								
Anxiety, HADS Scale 7.7 ± 2.3 6.6 ± 1.8 $.37$ Systolic blood pressure (mm Hg) 110 ± 17 114 ± 22 $.61$ Diastolic blood pressure (mm Hg) 71 ± 14 76 ± 12 $.33$ Cause of chronic heart failure 71 ± 14 76 ± 12 $.33$ Cause of chronic heart failure $12/14$ $10/12$ Alcoholism ratio $1/14$ $0/12$ Primary ratio $1/14$ $2/12$ Medications 8 $14/14$ $12/12$ Antiplatelet ratio $10/14$ $7/12$ Diuretic ratio $14/14$ $12/12$ ACE ratio $12/14$ $10/12$ Antiarrhythmic ratio $8/14$ $6/12$		423±78	423±98	1.00							
Systolic blood pressure (mm Hg) 110 ± 17 114 ± 22 .61Diastolic blood pressure (mm Hg) 71 ± 14 76 ± 12 .33Cause of chronic heart failureIschemic ratio $12/14$ $10/12$ Alcoholism ratio $1/14$ $0/12$ Primary ratio $1/14$ $0/12$ MedicationsBetablockers ratio $14/14$ $12/12$ Antiplatelet ratio $10/14$ $7/12$ Diuretic ratio $14/14$ $12/12$ AcE ratio $12/14$ $10/12$ AcE ratio $12/14$ $10/12$ Antiarrhythmic ratio $8/14$ $6/12$	Depression, HADS Scale	9.4±4.8		.74							
$\begin{array}{cccc} (mm \ Hg) & 110 \pm 17 & 114 \pm 22 & .61 \\ \hline \text{Diastolic blood pressure} & & & & & \\ (mm \ Hg) & 71 \pm 14 & 76 \pm 12 & .33 \\ \hline \text{Cause of chronic heart} & & & & & \\ failure & & & & & \\ \hline \text{Ischemic ratio} & 12/14 & 10/12 & & \\ \hline \text{Alcoholism ratio} & 1/14 & 0/12 & & \\ \hline \text{Primary ratio} & 1/14 & 2/12 & & \\ \hline \text{Medications} & & & & \\ \hline \text{Betablockers ratio} & 14/14 & 12/12 & & \\ \hline \text{Antiplatelet ratio} & 10/14 & 7/12 & \\ \hline \text{Diuretic ratio} & 14/14 & 12/12 & \\ \hline \text{ACE ratio} & 12/14 & 10/12 & & \\ \hline \text{Antiarrhythmic ratio} & 8/14 & 6/12 & & \\ \end{array}$	Anxiety, HADS Scale	7.7±2.3	6.6±1.8	.37							
Diastolic blood pressure (mm Hg) 71 ± 14 76 ± 12 .33Cause of chronic heart failure.33Ischemic ratio12/1410/12Alcoholism ratio1/140/12Primary ratio1/142/12Medications	Systolic blood pressure										
(mm Hg) 71±14 76±12 .33 Cause of chronic heart failure .33 Ischemic ratio 12/14 10/12 Alcoholism ratio 1/14 0/12 Primary ratio 1/14 2/12 Medications .33 Betablockers ratio 14/14 12/12 Antiplatelet ratio 10/14 7/12 Diuretic ratio 14/14 12/12 ACE ratio 12/14 10/12 Antiarrhythmic ratio 8/14 6/12	(mm Hg)	110±17	114±22	.61							
Cause of chronic heart failure Ischemic ratio 12/14 10/12 Alcoholism ratio 1/14 0/12 Primary ratio 1/14 2/12 Medications Betablockers ratio 14/14 12/12 Antiplatelet ratio 10/14 7/12 Diuretic ratio 14/14 12/12 ACE ratio 12/14 10/12 Antiarrhythmic ratio 8/14 6/12											
failureIschemic ratio12/1410/12Alcoholism ratio1/140/12Primary ratio1/142/12Medications200014/1412/12Antiplatelet ratio10/147/12Diuretic ratio14/1412/12ACE ratio12/1410/12Antiarrhythmic ratio8/146/12		71±14	76±12	.33							
Ischemic ratio 12/14 10/12 Alcoholism ratio 1/14 0/12 Primary ratio 1/14 2/12 Medications Betablockers ratio 14/14 12/12 Antiplatelet ratio 10/14 7/12 Diuretic ratio 14/14 12/12 ACE ratio 12/14 10/12 Antiarrhythmic ratio 8/14 6/12											
Alcoholism ratio1/140/12Primary ratio1/142/12MedicationsBetablockers ratio14/1412/12Antiplatelet ratio10/147/12Diuretic ratio14/1412/12ACE ratio12/1410/12Antiarrhythmic ratio8/146/12											
Primary ratio1/142/12Medications14/1412/12Betablockers ratio14/1412/12Antiplatelet ratio10/147/12Diuretic ratio14/1412/12ACE ratio12/1410/12Antiarrhythmic ratio8/146/12											
Medications14/1412/12Betablockers ratio14/1412/12Antiplatelet ratio10/147/12Diuretic ratio14/1412/12ACE ratio12/1410/12Antiarrhythmic ratio8/146/12			••••=								
Betablockers ratio14/1412/12Antiplatelet ratio10/147/12Diuretic ratio14/1412/12ACE ratio12/1410/12Antiarrhythmic ratio8/146/12	,	1/14	2/12								
Antiplatelet ratio10/147/12Diuretic ratio14/1412/12ACE ratio12/1410/12Antiarrhythmic ratio8/146/12											
Diuretic ratio14/1412/12ACE ratio12/1410/12Antiarrhythmic ratio8/146/12											
ACE ratio 12/14 10/12 Antiarrhythmic ratio 8/14 6/12	•										
Antiarrhythmic ratio 8/14 6/12											
Statins ratio 9/14 9/12	1										
	Statins ratio	9/14	9/12								

NOTE. Values are mean \pm SD or as otherwise noted. Abbreviation: ACE, angiotensin converting enzyme.

exercise), separated by 5 minutes of rest. Half of the CT was performed on a treadmill and half on a cycle ergometer (for practical and organizational reasons). CT was composed of a 10-minute warm-up followed by 45 minutes of aerobic exercise corresponding to the heart rate at the VT1 and a final 5 minutes of active recovery. Patients in the IT group practiced 168 minutes of exercise weekly, and patients in the CT group practiced 360 minutes of exercise weekly.

Tests

The cardiopulmonary test consisted of an exercise stress test performed on a treadmill with gas exchange measurements. The same test was performed at the beginning (t1) and the end (t2) of training on a treadmill,^a using a ramp protocol. After a 10-minute warm-up on the treadmill, the work load was increased progressively by 1.07km/h per minute, and the slope was increased by 1.9% per minute. The criteria used to end the exercise test stress were: symptoms of fatigue, dyspnea, or leg fatigue/pain.

A steep ramp test¹⁸ on a cycle ergometer was performed at the beginning of the rehabilitation, 1 day after the exercise stress test, only for patients in the IT group, to determine the intensity of training. After 10 minutes of cycling at 5W, the

	CT Group			IT Group		ANOVA			
Parameters	t1	t2	Change (%)	t1	t2	Change (%)	Group Effect (<i>P</i>)	Training Effect (<i>P</i>)	Interaction Effect (<i>P</i>)
Functional capacity									
Żo₂ (mL·min·kg)	10.6±4.1	10.8±4.1	2	10.7 ± 2.9	$13.6 \pm 3.2^{*}$	27	.272	<.001	.001
Exercise test									
duration (min)	3.5 ± 0.6	3.9±0.6	12	3.3±1.2	$4.9 \pm 0.6^{+}$	47	.673	<.001	.002
Oxygen pulse at maximal exercise (mL/									
beat)	6.6±3.3	6.3±3.5	-3	6.2±2.4	7.3±2.1*	18	.854	.292	.033
\dot{V}_{0_2} at the									
VT1 (mL·min·kg)	7.3±2.4	7.5±3.4	2	7.7±2.3	9.4±2.4 [†]	22	.240	.022	.059
Time at the									
VT1 (min)	1.1±0.5	$1.6 \pm 0.7^{+}$	45	1.3±2.0	2.7±0.8 [‡]	111	.043	<.001	.003
6MWT distance									
(m)	423.0±78.0	451±72*	6	423.0±98.0	475.0±52.0 [‡]	12	.648	<.001	.218
Symptoms of									
anxiety and									
depression									
Depression, HADS Scale	7.3±2.3	3.1±1.3*	58	6.6±1.8	3.4±2.5*	48	1.000	.080	.501
Anxiety, HADS	1.3-2.3	3.1±1.3"	00	0.0±1.0	3.4_2.5"	40	1.000	.080	.501
Scale	9.4±4.8	6.7±3.8*	29	8.8±3.5	6.5±3.1*	26	.910	.003	.792
	J.4_4.0	0.7 ± 3.0	23	0.0 - 0.0	0.0±0.1	20	.310	.005	.132

Table 2: Evolution of Functional Capacity and Syndrome of Anxiety and Depression

NOTE. Values are mean \pm SD or as otherwise indicated.

Abbreviation: ANOVA, analysis of variance.

[†]*P*<.01. [‡]*P*<.001.

F<.001.

load was increased by 25W every 10 seconds until exhaustion. The subject was instructed to cycle at a pedal frequency between 60 and 80 revolutions per minute (rpm). A physiotherapist supervised this test and encouraged patients. The test ended when the pedal frequency fell below 50 rpm and when the patient was exhausted.

The functional capacity was assessed at t1 and at t2 using a 6MWT. It was conducted following a standardized protocol described by guidelines and in a 20-m flat obstacle free corridor.¹⁹ This test assesses the submaximal level of functional capacity. It was performed 1 day after the stress test.

Measurements

Gas exchanges were measured during the exercise stress test.^b It provided measurement of Vo₂peak and the VT1.²⁰ Peak $\dot{V}o_2$ was determined as the $\dot{V}o_2$ achieved at the patient's peak work load, an average over the last 15 seconds. The VT1 was determined by visual inspection of the breakpoints in the pulmonary ventilation $\dot{V}o_2$. Gas analyzers and flow probes were calibrated before each test.

The level of anxiety and depression was measured using the Hospital Anxiety and Depression Scale $(HADS)^{21}$ by a psychologist, the same day of the stress test. The HADS Scale can screen for the most common psychological disorders: anxiety and depression. This test can validate the existence of symptoms and evaluates their severity.²²

Statistical Analysis

Results were expressed as mean \pm SD. For baseline characteristics, means of continuous variables were compared by paired Student *t* test. The sample size of the study was calculated to detect a mean difference of at least $3mL \cdot kg^{-1} \cdot min^{-1}$ between the groups, with a common SD of $2.5\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$, with 80% power and a significance level of .05. A two-way, repeated-measures analysis of variance with group and time as factors was employed. When a significant effect of factors or interaction (group × time) was observed, a post hoc test (Tukey) was performed for each variable in order to identify the differences. In case of a significant difference in a variable in both groups, the variation (t2–t1) was compared using a Student *t* test. *P*<.05 was considered statistically significant. All analyses were performed using SigmaStat software.^c

RESULTS

At baseline of cardiac rehabilitation, disease etiology and medications were similar for both groups, and no more therapeutic changes had occurred in the rehabilitation program (see table 1). The pharmacologic treatment was comparable between the groups.

Peak \dot{Vo}_2 , exercise test duration, oxygen pulse at maximal exercise, and \dot{Vo}_2 at the VT1 increased significantly after 8 weeks of IT, while no significant change was observed after CT for these variables (table 2). The time corresponding to the VT1 and the distance at the 6MWT were significantly improved after IT and CT. This increase in the time at the VT1 was, however, significantly higher with IT than with CT (fig 1). Lastly, the level of anxiety and depression was significantly improved by both training methods. This improvement was not significantly different between IT and CT.

The adherence to the training was 100% with no dropouts. It should be noted that no cardiac event and no major decompensation were observed.

^{*}*P*<.05.




Fig 1. Improvement in time at the VT1. **P<.01: difference between IT and CT.

DISCUSSION

The major finding of the present study was that a short IT program performed at high intensity induced significant improvement in the functional physical capacity in patients with chronic heart failure, while CT had fewer effects on this capacity. Indeed, in CT we observed an increase in the time at the VT1 but no significant change in Vo2peak, exercise test duration, and $\dot{V}O_2$ at the VT1, while we found that IT significantly increased Vo₂peak, exercise test duration, time at the VT1, and $\dot{V}O_2$ at the VT1, indicating an improvement in exercise tolerance. The VT1 reflects the degree of deconditioning, and the increase of time and \dot{V}_{0_2} at the VT1 suggest a delayed intervention of the anaerobic pathways for energy production.²³ Indeed, Vo₂peak and $\dot{V}o_2$ at the VT1 were improved by 27% and 22%, respectively, which is similar to previous studies in patients with coronary artery disease (17%-46%) for the increase in Vo₂peak and 23\%-42\% for the increase in \dot{Vo}_2 to the VT1^{12,15,16,24-26}). The increase in Vo₂peak was approximately 1 metabolic equivalent task (MET) in IT. This increase appears to be considerable, because according to the dose-response analyses, a 1 MET higher level of maximal aerobic capacity is associated with 13% and 15% decrements in risk of all mortality and coronary heart disease.²⁷ Tabet et al²⁸ showed that a lack of increase in exercise capacity with training (evaluated by Vo₂peak) in patients with chronic heart failure has strong prognostic value for cardiac events. Patients that do not respond to rehabilitation, as defined by an improvement of less than 6% in the ratio of Vo₂peak, were 8 times more likely to have a cardiac event over the next 16 months.²

Currently, there is no consensus on the optimal intensity of exercise for rehabilitation in patients with heart failure.²⁹ IT used in our study is innovative, because the exercise intensity was higher than the previously used protocols. Indeed, IT was performed with exercises at 50% and 80% of the maximal power reached during a steep ramp test during the first 4 weeks and the last 4 weeks, respectively. According to the method proposed by De Backer et al,³⁰ we calculated that these intensities corresponded to about 80% and 120% of the maximal power reached during the stress test. Therefore, IT can be actually considered as a very high-intensity IT. In most of the

previous studies on the effects of IT in cardiac failure populations, the intensity of exercises was between 80% and 95% of Vo₂peak during 2 to 5 minutes, and these exercise periods were separated by moderate-intensity exercises between 40% and 70% of Vo₂peak.^{11,12,15,16,24-26} The duration of exercise of our protocol was also shorter (30s), and exercises were separated by 1 minute of complete rest. The short periods of exercise as well as the long periods of rest (about two thirds of rest in a training session) proposed in our study seemed more achievable for very deconditioned patients, as suggested earlier by Meyer et al.¹⁸ Lastly, it should be noted that previous studies reported changes after 10 to 52 weeks of training.^{11,15,24} We studied the effect of a training period of only 8 weeks of rehabilitation, performed 5 days per week. This corresponds to the period of rehabilitation commonly prescribed in France.

The distance performed during the 6MWT is an objective measure of functional capacity. Previous studies have qualified the 6MWT as a valid and reliable test to measure the functional capacity in patients with chronic heart failure.^{31,32} Our results show that IT and CT significantly increased the distance at the 6MWT. The 6MWT globally evaluates the responses of all the systems involved during exercise, including the pulmonary and cardiovascular systems.¹⁹ The minimal clinical important difference (MCID) in the 6MWT is 43m in patients with chronic heart failure.¹⁹ Our results show that IT generates an average improvement of 52m, and CT an average improvement of 28m. IT induced an MCID, while CT did not induce this improvement. Moreover, the 6MWT is a fairly accurate predictor of increased mortality and morbidity of heart disease.^{19,33} Therefore, in accordance with our results on exercise tolerance, it suggests higher adaptations after IT.

It was already established that a rehabilitation program contributes to diminished levels of anxiety and depression.^{34,35} In accordance with that, IT and CT groups of the present study showed significant improvements in the symptoms of anxiety and depression. No difference between IT and CT was found, indicating that the modalities of training had no effect on these symptoms. This result put forward the significant contribution of physical training programs associated with multidisciplinary support in the improvement of anxiety and depression levels of patients in cardiovascular rehabilitation programs.

It was shown in healthy subjects that IT seems optimal in maximizing both peripheral muscle and central cardiorespira-tory adaptations.¹⁴ Indeed, the constant submaximal oxygen requirement during CT would be mainly associated with greater oxygen extraction by muscles, while the fluctuation of a high oxygen requirement during IT would induce improvements in cardiac output and oxygen extraction.¹⁴ In patients with heart failure, interval exercise would allow more intense exercise stimuli on peripheral muscles with no greater left ventricular stress than when using a steady state training method.²⁶ Because the intensity of exercise may be an important factor for reversing left ventricular remodeling,12 this method of training is interesting for patients with heart failure. The IT at very high intensities in these patients could have induced central and peripheral adaptations. Future investigations should address the acute responses of intermittent exercise in patients with chronic heart failure; this will help support the findings from the present study.

Study Limitations

The number of patients in the present study was small, and subjects were predominantly men. This study clearly demonstrates that this short IT program was sufficient to induce a significant effect on the functional physical capacity in patients with chronic heart failure. However, our study gives no information about the long-term consequences of such a short IT program. In addition, further studies seem necessary to determine the optimal duration of training using an IT program.

CONCLUSIONS

The present study demonstrates that a rehabilitation program of 8 weeks with very high-intensity IT in patients with chronic heart failure can result in considerable improvements in physical capacity. These parameters are considered prognostic markers of chronic heart failure. CT programs seem to have lower impact on this capacity. These results can contribute to improve the workout training intervals used for these patients. Moreover, this type of protocol is much more feasible and accessible by such patients. However, with regards to the size of population and number of parameters studied, our results remain to be confirmed by more extensive studies.

Acknowledgments: We thank the team of the Sainte Clotilde Cardiac Rehabilitation Center for their cooperation, A.L. Diquelou and A. Descamps for their help, and S. Jhowry for her translation assistance.

References

- 1. Tabet J, Meurin P, Driss AB, et al. Benefits of exercise training in chronic heart failure. Arch Cardiovasc Dis 2009;102:721-30.
- Coats AJ, Adamopoulos S, Radaelli A, et al. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function. Circulation 1992;85:2119-31.
- Wielenga RP, Huisveld IA, Bol E, et al. Safety and effects of physical training in chronic heart failure. Results of the Chronic Heart Failure and Graded Exercise study (CHANGE). Eur Heart J 1999;20:872-9.
- Iliou MC. [Role of rehabilitation in the treatment of chronic heart insufficiency] [French]. Ann Cardiol Angeiol (Paris) 2001;50: 65-73.
- Conraads VM, Beckers P, Vaes J, et al. Combined endurance/ resistance training reduces NT-proBNP levels in patients with chronic heart failure. Eur Heart J 2004;25:1797-805.
- Hambrecht R, Gielen S, Linke A, et al. Effects of exercise training on left ventricular function and peripheral resistance in patients with chronic heart failure: a randomized trial. JAMA 2000;283: 3095-101.
- Hambrecht R, Fiehn E, Weigl C, et al. Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. Circulation 1998;98:2709-15.
- Adamopoulos S, Coats AJ, Brunotte F, et al. Physical training improves skeletal muscle metabolism in patients with chronic heart failure. J Am Coll Cardiol 1993;21:1101-6.
- 9. Belardinelli R, Georgiou D, Cianci G, Purcaro A. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation 1999;99:1173-82.
- Piepoli MF, Davos C, Francis DP, Coats AJ; ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328:189.
- 11. Nilsson B, Westheim A, Risberg M. Effects of group-based highintensity aerobic interval training in patients with chronic heart failure. Am J Cardiol 2008;102:1361-5.
- Wisloff U, Stoylen A, Loennechen JP, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation 2007;115:3086-94.
- Cornish AK, Broadbent S, Cheema BS. Interval training for patients with coronary artery disease: a systematic review. Eur J Appl Physiol 2010;111:579-89.

- Daussin FN, Zoll J, Dufour SP, et al. Effect of interval versus continuous training on cardiorespiratory and mitochondrial functions: relationship to aerobic performance improvements in sedentary subjects. Am J Physiol Regul Integr Comp Physiol 2008; 295:R264-72.
- 15. Rognmo Ø, Hetland E, Helgerud J, Hoff J, Slørdahl SA. High intensity aerobic interval exercise is superior to moderate intensity exercise for increasing aerobic capacity in patients with coronary artery disease. Eur J Cardiovasc Prev Rehabil 2004;11:216-22.
- Ehsani AA, Heath GW, Hagberg JM, Sobel BE, Holloszy JO. Effects of 12 months of intense exercise training on ischemic ST-segment depression in patients with coronary artery disease. Circulation 1981;64:1116-24.
- [Recommendation of the French Society of Cardiology concerning the practice of cardiovascular rehabilitation in adults] [French]. Arch Mal Coeur Vaiss 1998;(1 Suppl):50-62. [No authors listed].
- Meyer K, Samek L, Schwaibold M, et al. Interval training in patients with severe chronic heart failure: analysis and recommendations for exercise procedures. Med Sci Sports Exerc 1997;29: 306-12.
- ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the sixminute walk test. Am J Respir Crit Care Med 2002;166:111-7.
- Wasserman K, Whipp BJ, Koyl SN, Beaver WL. Anaerobic threshold and respiratory gas exchange during exercise. J Appl Physiol 1973;35:236-43.
- Spinhoven P, Ormel J, Sloekers PP, Kempen GI, Speckens AE, Van Hemert AM. A validation study of the Hospital Anxiety and Depression Scale (HADS) in different groups of Dutch subjects. Psychol Med 1997;27:363-70.
- 22. Snaith RP. The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes 2003;1:29.
- Tabet JY, Meurin P, Ben Driss A, Weber H, Renaud N, Cohen-Solal A. [Exercise training in cardiac patients: usefulness of the cardiopulmonary exercise test] [French]. Ann Cardiol Angeiol (Paris) 2006;55:178-86.
- Ehsani AA, Martin WH, Heath GW, Coyle EF. Cardiac effects of prolonged and intense exercise training in patients with coronary artery disease. Am J Cardiol 1982;50:246-54.
- Warburton DE, McKenzie DC, Haykowsky MJ, et al. Effectiveness of high-intensity interval training for the rehabilitation of patients with coronary artery disease. Am J Cardiol 2005;95: 1080-4.
- 26. Munk PS, Staal EM, Butt N, Isaksen K, Larsen AI. High-intensity interval training may reduce in-stent restenosis following percutaneous coronary intervention with stent implantation. A randomized controlled trial evaluating the relationship to endothelial function and inflammation. Am Heart J 2009;158:734-41.
- Kodama S, Saito K, Tanaka S, et al. Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA 2009; 301:2024-35.
- Tabet J, Meurin P, Beauvais F, et al. Absence of exercise capacity improvement after exercise training program: a strong prognostic factor in patients with chronic heart failure. Circ Heart Fail 2008; 1:220-6.
- 29. Working Group on Cardiac Rehabilitation & Exercise Physiology and Working Group on Heart Failure of the European Society of Cardiology. Recommendations for exercise training in chronic heart failure patients. Eur Heart J 2001;22:125-35.
- 30. De Backer IC, Schep G, Hoogeveen A, Vreugdenhil G, Kester AD, van Breda E. Exercise testing and training in a cancer rehabilitation program: the advantage of the steep ramp test. Arch Phys Med Rehabil 2007;88:610-6.

- 31. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-23.
- 32. Kervio G, Ville NS, Leclercq C, Daubert J, Carré F. Intensity and daily reliability of the six-minute walk test in moderate chronic heart failure patients. Arch Phys Med Rehabil 2004;85:1513-8.
- 33. Passantino A, Lagioia R, Mastropasqua F, Scrutinio D. Short-term change in distance walked in 6 min is an indicator of outcome in patients with chronic heart failure in clinical practice. J Am Coll Cardiol 2006;48:99-105.
- 34. Duarte Freitas P, Haida A, Bousquet M, Richard L, Mauriège P, Guiraud T. Short-term impact of a 4-week intensive cardiac re-

habilitation program on quality of life and anxiety-depression. Ann Phys Rehabil Med 2011;54:132-43.

35. Lavie CJ, Milani R. Benefits of cardiac rehabilitation in the elderly. Chest 2004;126:1010-2.

Suppliers

- MTM-1500 med; Schiller Medical SAS, 4 Rue Louis Pasteur 67160 Wissembourg, France.
- b. Medisoft SA, P.A.E de Sorinne, Route de la Voie Cuivrée, 1 B-5503 SORINNES, Belgium.
- c. SigmaStat; Systat Software, Inc, 225 W Washington St, Ste 425, Chicago, IL 60606.